Germany is developing a pharmaceutical pricing proposal for the Trump administration in an effort to avert potential US tariffs on German goods, reports Politico citing sources

Sector-specific concessions offered to head off broad tariffs follow a familiar pattern in this administration's trade posture: an across-the-board or country-targeted tariff threat is announced, affected governments and industries propose narrower accommodations, and outcomes range from partial carve-outs to the threat lapsing entirely. Pharmaceuticals sit in a distinct position within that pattern, since drug pricing is a stated domestic priority for Washington, which gives a pricing proposal more traction than a pure quota or purchase commitment of the kind seen in past negotiations. The actors matter here: Berlin proposing on behalf of its pharmaceutical exporters suggests the approach is industry-backed, and precedents of this kind have tended to require EU-level coordination before they stick, since trade policy is a Brussels competence rather than a national one. The tell in episodes like this is whether the White House treats the proposal as a template applicable to other exporting nations or as a one-off, and whether the tariff clock, if one is running, pauses while talks proceed. Attribution to sources rather than official confirmation leaves the usual risk that the proposal is a negotiating position floated to gauge reaction. Worth noting that tariff threats against allies have historically produced initial risk-off moves in the affected equity sector and the relevant FX cross, with retracement as accommodation becomes the base case.